Insider Trading : Thur 5/18/23

Notable purchases -- President/CEO adds to LAZR; notable sales -- Deputy CFO active in MS

Buyers:

• ADC President/Chief Executive Officer and the Chief Operating Officer bought a total of 6,500 shares at $65.25 - $65.50 worth ~$425K.
• ADV Chief Executive Officer bought 160,000 shares at $1.47 - $1.66 worth ~$258K.
• AFCG Chief Executive Officer / 10% owner bought 51,309 shares at $10.44 - $10.45 worth ~$536K.
• AXON Director bought 10000 shares at $199.14 - $200.25 worth ~$2.0 mln.
• INSM Director bought 20,000 shares at $19.22 - $19.35 worth ~$386K.
• LAZR Chairperson, President & CEO bought 1,475,685 shares at $5.81 - $6.33 worth ~$8.9 mln.

Sellers:

• AMC 10% owner sold 1,235,947 AMC Preferred Equity Units (APE) at $1.60 - $1.63 worth ~$2.0 mln.
• CBZ Director sold 15,000 shares at $49.73 - $50.28 worth ~$750K.
• MS Deputy Chief Financial Officer sold 7320 shares at ~$82.9505 worth ~$607K.
• ONEW Director sold 60,353 shares at $28.10 - $28.36 worth ~$1.7 mln.
• WTS 10% owner sold 7,000 shares at  $165.00 - $165.37 worth ~$1.2 mln.

This week's biggest % winners & losers : June 4 - 8, 18 (wk 23)

The following are this week's top 20 percentage gainers and top 20 percentage losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top 20 % gainers

• Healthcare: AXON (4.8 +150%), GHDX (51.46 +29.67%), TXMD (7.42 +26.84%), ENDP (7.67 +21.75%), ENTA (116.92 +18.39%)
• Industrials: RRTS (2.24 +28%), NCS (23 +22.67%)
• Consumer Discretionary: CONN (34.35 +51.99%), FIVE (101.19 +41.74%), ASNA (4.58 +37.95%), SFIX (24.88  +31.09%),  SONC (31.89 +30.59%), CWH (24.59 +30.59%), SIG (55.41 +30.04%), VRA (14.74 +22.63%), ANF (26.27 +20.67%), FOSL (28.4 +19.83%), JCP (2.82 +19.49%)

This week's top 20 % losers

• Healthcare: NKTR (54.14 -40.08%), MDXG (6.09 -23.2%), BPMC (66.87 -20.85%), ADRO (6.85 -18.93%), OMER (18.33 -12%), ATRA (45 -9.91%)
• Consumer Discretionary: TEDU (7.81 -19.15%)
• Information Technology: JKS (11.8 -22.06%), CSIQ (12.34 -21.35%), FSLR (52.67 -20.11%), SPWR (7.05 -16.47%), AMBA (42.66 -13.2%), MKSI (103.15 -10.23%)
• Energy: RES (14.11 -11.37%)
• Consumer Staples: UNFI (39.85 -14.01%), AVP (1.61 -10.56%)
• Utilities: EBR (3.48 -14.5%)

Axovant (AXON) : licenses a gene therapy treatment for Parkinson's disease

 

** the following day **

Axovant Sciences licenses exclusive worldwide rights to develop and commercialize OXB-102 (now AXO-Lenti-PD) from Oxford BioMedica

AXO-Lenti-PD is an investigational gene therapy for Parkinson's disease that delivers three genes encoding a critical set of enzymes required for dopamine synthesis in the brain. Oxford BioMedica is a world leader in lentiviral vector product development and manufacturing, and will be the clinical and commercial supplier of AXO-Lenti-PD. Axovant expects to initiate a Phase 1/2 dose escalation study of AXO-Lenti-PD in patients with advanced Parkinson's disease by the end of 2018.

• Under the terms of the license agreement with Oxford BioMedica, Axovant obtained rights to AXO-Lenti-PD, as well as its predecessor product ProSavin, for an initial payment of $30 million in cash, $5 million of which will be applied as a credit against the process development work and clinical supply that Oxford BioMedica will provide to Axovant. Oxford BioMedica is also eligible to receive additional development, regulatory, and commercial milestone payments potentially in excess of $812 million, and tiered royalties on net sales of AXO-Lenti-PD, if approved.
• Roivant has agreed to purchase $25 million of Axovant common shares, which will support the clinical development of AXO-Lenti-PD and additional business development activities.
• Fraser Wright, PhD, will join Axovant as Chief Technology Officer overseeing the company's gene therapy initiatives. Dr. Wright is the Co-Founder and former Chief Technology Officer of Spark Therapeutics (ONCE).

** charts day before **

 

AXON — is it a buy?

•  Aug 30:  Is AXON a buy? 

• A month later:

AXON — is it a buy?

• Apr 13:  Is AXON a buy? 

• 2 months later:

TASER International (NASDAQ:TASR) changes its name to Axon Enterprise (NASDAQ:AAXN)

Scottsdale, AZ-based Taser International Inc. is changing its name to better reflect the company’s push to make its wearable Axon body cameras available to all police officers.

• April 2017: TASER International changed its name to Axon Enterprise, Inc. and began trading under the ticker symbol AAXN. 
• January 2021: Axon Enterprise changed its ticker symbol to AXON, previously used by Axovant (AXON). 

Since its inception, the TASER name has become synonymous with iconic, less-lethal weapons. Today, the company’s portfolio has grown to encompass a much wider range of technologies, including a rich ecosystem of connected devices and software applications.

Taser will now be called Axon Enterprise Inc. Taser (Nasdaq: TASR) is changing its stock ticker to AAXN effective the opening of the Nasdaq market on April 6.